Vimta Labs Ltd.

BSE: VIMTALABS524394ISIN INE579C01029

Healthcare
Healthcare Research, Analytics & Technology
BSE Healthcare

Share price

₹498.80+12.65 (+2.60%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

Splits and bonuses

13 Jun 2025 · Bonus 1:1

52W high: ₹686.35
52W low: ₹377.30
Off 52W high: -27.33%
1M return: -12.69%
3M return: -24.06%
6M return: -2.36%
1Y return: -24.58%
20D avg volume: 8,835
50 DMA: ₹574.68
200 DMA: ₹524.12

Key ratios Consolidated

Market cap: ₹2,230 Cr
Current price: ₹498.80
52W high / low: ₹686.35 / ₹377.30
Face value: ₹2.00
P/E: 0.00
P/B: —
EPS (TTM): ₹0.00
Book value / share: —
ROE: —
ROCE: —
Operating margin: —
Net margin: —
Debt / equity: —
Net debt: —
Interest cover: 26.70
Dividend yield: 0.40%
Dividend / share (TTM): ₹2.00
Payout: —
Cash conversion cycle: —

Financials

Metric	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22
Income statement
	89.92	84.74	81.75	79.69	81.68	73.41	83.48	81.82	77.38	79.85	79.13	74.09
	1.23	0.68	0.69	0.49	0.90	2.04	0.59	0.67	1.12	0.76	0.89	0.44
	91.15	85.43	82.45	80.18	82.57	75.44	84.07	82.49	78.51	80.62	80.02	74.53
	67.23	63.53	65.92	63.89	69.07	67.06	67.77	65.93	64.43	62.86	63.42	58.30
	20.63	18.35	18.72	17.66	19.68	18.27	20.57	18.90	18.80	16.72	19.32	17.29
	23.37	23.94	24.52	23.74	25.55	25.34	24.66	22.00	23.06	23.30	22.71	21.07
	0.58	0.41	0.48	0.53	0.54	0.61	0.44	0.25	0.65	0.80	0.94	0.57
	9.81	8.29	8.21	8.09	8.69	8.92	8.49	8.04	7.85	7.58	7.25	6.68
	12.85	12.55	14.00	13.81	14.60	13.90	13.60	16.68	14.06	14.44	13.17	12.66
	23.92	21.89	16.52	16.28	13.51	8.39	16.30	16.55	14.08	17.76	16.60	16.23
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	23.92	21.89	16.52	16.28	13.51	8.39	16.30	16.55	14.08	17.76	16.60	16.23
	6.40	4.88	4.24	3.93	3.37	2.06	4.11	3.87	3.84	4.55	4.57	4.39
	21.50	15.25	12.28	12.35	10.13	6.33	12.20	12.68	10.24	13.21	12.04	11.83
	7.86	7.68	5.54	5.58	4.57	2.85	5.51	5.73	4.62	5.97	5.45	5.36
Key metrics
	34.31	30.59	25.21	24.90	22.74	17.92	25.23	24.84	22.58	26.14	24.79	23.48
	38.20%	36.10%	30.80%	31.20%	27.80%	24.40%	30.20%	30.40%	29.20%	32.70%	31.30%	31.70%
	23.90%	18.00%	15.00%	15.50%	12.40%	8.60%	14.60%	15.50%	13.20%	16.50%	15.20%	16.00%
	10.10%	15.40%	-2.10%	-2.60%	5.60%	-8.10%	5.50%	10.40%	—	—	—	—
	112.20%	140.90%	0.70%	-2.60%	-1.10%	-52.10%	1.30%	7.20%	—	—	—	—

Metric	TTM	FY24	FY23	FY22
Income statement
	336.10	318.26	318.19	278.28
	3.09	4.01	3.44	1.45
	339.21	322.27	321.63	279.73
	260.57	267.79	256.64	222.82
	75.36	76.18	73.74	78.93
	95.57	99.28	91.08	75.98
	2.00	2.12	2.65	1.50
	34.40	34.20	30.71	23.33
	53.21	55.90	58.35	42.81
	78.61	54.48	65.00	56.91
	0.00	0.00	0.00	-1.22
	78.61	54.48	65.00	55.69
	19.45	13.47	16.82	14.36
	61.38	41.01	48.17	41.33
	26.66	18.51	21.77	18.70
Key metrics
	115.01	90.80	98.36	80.52
	34.22%	28.50%	30.90%	28.90%
	18.26%	12.90%	15.10%	14.90%
	4.90%	0.00%	14.30%	—
	48.48%	-14.90%	16.50%	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	111.98	109.07	109.25	98.63	101.85	97.56	94.44	88.52	83.14	80.20	78.34	80.10
	2.90	3.81	2.75	1.83	2.66	1.75	1.64	1.23	0.68	0.69	0.49	0.89
	114.89	112.89	112.00	100.46	104.51	99.31	96.08	89.75	83.83	80.89	78.83	80.99
	87.36	84.55	82.95	75.48	78.23	74.05	71.05	66.50	62.83	65.22	63.27	68.39
	26.15	22.67	22.48	19.36	20.15	18.81	18.18	20.41	18.15	18.49	17.46	19.42
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	30.67	29.42	29.57	28.41	28.61	27.82	27.26	23.14	23.72	24.28	23.55	25.34
	0.39	0.24	0.32	0.16	0.37	0.32	0.44	0.58	0.41	0.48	0.53	0.53
	12.87	12.55	12.75	10.92	10.24	9.86	9.21	9.74	8.22	8.15	8.03	8.64
	17.29	19.67	17.83	16.64	18.86	17.25	15.96	12.64	12.34	13.83	13.63	14.44
	27.52	28.34	29.05	24.99	26.27	25.26	25.03	23.25	21.00	15.67	15.55	12.60
	0.00	0.00	0.00	-1.62	0.00	0.00	0.00	—	—	—	—	—
	27.52	28.34	29.05	23.37	26.27	25.26	25.03	23.25	21.00	15.67	15.55	12.60
	6.91	7.30	7.93	5.79	6.35	6.37	6.71	6.21	4.64	4.03	3.75	3.14
	20.61	21.04	21.11	17.59	19.92	18.89	18.32	21.02	14.59	11.64	11.80	9.46
	4.61	4.71	4.73	3.96	4.46	4.25	8.22	7.65	7.38	5.25	5.34	4.26
Key metrics
	40.78	41.13	42.12	34.45	36.88	35.44	34.68	33.57	29.63	24.30	24.11	21.77
	36.40%	37.70%	38.60%	34.90%	36.20%	36.30%	36.70%	37.90%	35.60%	30.30%	30.80%	27.20%
	18.40%	19.30%	19.30%	17.80%	19.60%	19.40%	19.40%	23.70%	17.50%	14.50%	15.10%	11.80%
	5.30%	—	5.90%	—	5.90%	—	6.30%	—	—	—	—	—
	9.90%	11.80%	15.70%	11.40%	22.50%	21.60%	20.60%	10.50%	—	—	—	—
	3.50%	11.40%	15.20%	-16.30%	36.50%	62.30%	55.30%	122.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	428.93	407.29	343.98	312.89	315.12	275.98
	11.29	8.99	4.24	4.01	3.47	1.45
	440.24	416.28	348.22	316.90	318.58	277.43
	330.34	310.71	259.22	265.36	254.75	220.86
	90.66	80.79	71.45	75.41	73.37	78.46
	0.00	0.00	0.00	—	—	—
	118.07	114.41	97.02	98.49	90.37	75.41
	1.11	1.17	1.90	2.11	2.64	1.50
	49.09	43.77	35.29	34.00	30.54	23.16
	71.43	70.57	53.57	55.25	57.72	42.07
	109.90	105.57	89.00	51.54	63.83	56.57
	-1.62	-1.62	0.00	—	—	-1.22
	108.28	103.95	89.00	51.54	63.83	55.35
	27.93	26.44	22.25	12.73	16.53	14.29
	80.35	77.51	67.34	38.81	47.30	41.06
	18.01	17.40	30.28	17.52	21.37	18.57
Key metrics
	158.48	148.89	126.19	87.65	97.01	80.01
	36.95%	36.60%	36.70%	28.00%	30.80%	29.00%
	18.73%	19.00%	19.60%	12.40%	15.00%	14.90%
	—	21.20%	22.60%	—	—	—
	12.18%	18.40%	9.90%	-0.70%	14.20%	—
	2.82%	15.10%	73.50%	-17.90%	15.20%	—
	—	47.46	15.55	—	—	—
	—	1.90	1.40	—	—	—
	—	0.01	0.02	—	—	—
	—	-19.64	-7.33	—	—	—
	—	111.1	128.2	—	—	—
Balance sheet
	—	562.23	466.53	—	—	—
	—	224.87	187.82	—	—	—
	—	22.97	15.84	—	—	—
	—	105.70	106.24	—	—	—
	—	29.95	25.06	—	—	—
	—	19.82	21.71	—	—	—
	—	300.21	223.57	—	—	—
	—	11.66	10.49	—	—	—
	—	65.52	64.37	—	—	—
	—	3.33	8.51	—	—	—
	—	1.77	5.29	—	—	—
	—	1.56	3.22	—	—	—
	—	456.87	378.85	—	—	—
Cash flow
	—	147.14	94.61	—	—	—
	—	-129.67	-75.54	—	—	—
	—	-10.35	-16.68	—	—	—
	—	99.68	79.06	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +8.93%
Sales CAGR 5Y: —
Profit CAGR 3Y: +17.90%
Profit CAGR 5Y: —
Sales YoY (TTM): +12.18%
Profit YoY (TTM): +2.82%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +4.90%
Profit YoY (TTM): +48.48%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 35.63%

Quarter	September 2026	June 2026
Promoter %	35.63%	35.65%

Holder	Type	Holding	Previous	Change
EUROFINS ANALYTICAL SERVICES INDIA PVT LTD	Public	19.70%	19.72%	-0.02%
SIVALINGA PRASAD VASIREDDI	Promoter	11.63%	11.63%	0.00%
LCGC CHROMATOGRAPHY SOLUTIONS PRIVATE LIMITED	Public	9.32%	9.33%	-0.01%
VANGAL HARRIMAN	Promoter	6.90%	6.91%	-0.01%
PRAVEENA VASIREDDI	Promoter Group	4.70%	4.71%	-0.01%
TELANGANA STATE INDUSTRIAL DEVELOPMENT CORPORATION LIMITED	Promoter	2.64%	2.64%	0.00%
RAJYA LAKSHMI VASIREDDI	Promoter Group	2.56%	2.56%	0.00%
VASIREDDI VEERABHADRA PRASAD	Promoter	2.30%	2.30%	0.00%
BARCA GLOBAL MASTER FUND LP	Public	2.27%	2.27%	0.00%
SUJANI VASIREDDI	Promoter Group	1.86%	1.86%	0.00%
VUNGAL RAJESWARI	Promoter Group	0.89%	0.89%	0.00%
HARITA VASIREDDI	Promoter Group	0.75%	0.75%	0.00%
SIREESH CHANDRA VUNGAL	Promoter Group	0.73%	0.73%	0.00%
SUDHESHNA VUNGAL	Promoter Group	0.67%	0.67%	0.00%
SWARNA LATHA VASIREDDI	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Syngene International Limited	16,841	417.20	90.49	8.40%	-5.99% TTM	-60.25% TTM	-35.44%
Indegene Limited	14,870	617.05	36.17	15.40%	+35.84% TTM	-7.78% TTM	+14.61%
Suven Life Sciences Ltd.	7,803	276.15	-22.14	-46.50%	+17.29% TTM	-91.30% TTM	+40.18%
Vimta Labs Ltd.	2,230	498.80	—	—	+4.90% TTM	+48.48% TTM	-24.58%
NOVELIX PHARMACEUTICALS LIMITED S	194	68.00	53.54	6.70%	+179.89% TTM	+535.09% TTM	+29.52%
Bilcare Ltd.	183	77.69	16.51	9.20%	+11.44% TTM	+125.02% TTM	-25.62%
TAKE LIMITED S	170	11.47	29.00	11.10%	-15.35% TTM	+124.35% TTM	-52.11%
Jeevan Scientific Technology Limited	164	81.70	32.02	4.80%	+66.05% TTM	+222.49% TTM	+30.72%
GlobalSpace Technologies Limited	99	28.84	29.21	5.00%	+37.21% TTM	+398.53% TTM	+63.12%
Adeshwar Meditex Limited S	27	18.80	21.36	6.00%	—	—	+1.62%
Vanta Bioscience Limited	14	20.39	—	1.50%	—	—	-5.86%

Filings & corporate actions

Recent announcements

Transcript of the FY / Q2 - 2026-27 Earnings / Investor Call held on 30th October 2026.4 Nov 2026 · Company Update / Earnings Call Transcript
Newspaper Publication of Unaudited Financial Results - Q2 FY 2026-2731 Oct 2026 · Company Update / Newspaper Publication
Incorporation of a Wholly Owned Subsidiary in the United States of America (USA).30 Oct 2026 · Company Update / Acquisition
Audio Recording of the Earnings Call for Q2 FY 2026-27.30 Oct 2026 · Company Update / Analyst / Investor Meet
Press Release - Unaudited Financial Results - 30th September 2026.30 Oct 2026 · Company Update / Press Release / Media Release
Investor Presentation - Q2 Results - FY 2026-2730 Oct 2026 · Company Update / Investor Presentation
Unaudited Financial Results for the 2nd Quarter and Half Year ended 30.09.2026.30 Oct 2026 · Result / Financial Results
Unaudited Financial Results for the 2nd Quarter and Half Year ended 30.09.2026.30 Oct 2026 · Board Meeting / Outcome of Board Meeting
Intimation of Schedule of Analyst/Investor Conference call.26 Oct 2026 · Company Update / Analyst / Investor Meet
Vimta Labs Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....24 Oct 2026 · Board Meeting / Board Meeting
Certificate pursuant to Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018.13 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation for closure of Trading Window.30 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Allotment of Employee Stock Options under "Vimta Labs Employee Stock Option Plan 2021".16 Sep 2026 · Company Update / Allotment of ESOP / ESPS
Intimation of Schedule of Analyst/ Institutional Investor Meet.8 Sep 2026 · Company Update / Analyst / Investor Meet
Disclosure on Credit Rating.2 Sep 2026 · Company Update / Credit Rating
Reply to the clarification regarding increase in volume.1 Sep 2026 · Company Update / General
The Exchange has sought clarification from Vimta Labs Ltd on September 01, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.1 Sep 2026 · Company Update / Clarification
Intimation of Schedule of Analyst/Institutional Investor Meet.29 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation of Schedule of Analyst/Institutional Investors Meet.29 Aug 2026 · Company Update / Analyst / Investor Meet
Intimation on cyber security incident21 Aug 2026 · Company Update / General
Intimation of Schedule of Analyst Meeting.28 Jul 2026 · Company Update / Analyst / Investor Meet
Intimation of Schedule of Analyst Meeting.28 Jul 2026 · Company Update / Analyst / Investor Meet
Transcript - Q1 Earnings Conference Call- FY 2026-2724 Jul 2026 · Company Update / Earnings Call Transcript
Newspaper Publication - Q1 FY 2026-2721 Jul 2026 · Company Update / Newspaper Publication
Q1 - FY 2026-27 - Audio Recording of the Earnings Call.20 Jul 2026 · Company Update / Analyst / Investor Meet
Press Release - Unaudited Financial Results - 30.06.2026.20 Jul 2026 · Company Update / Press Release / Media Release
Investor Presentation - Q1 FY 2026-2720 Jul 2026 · Company Update / Investor Presentation
Unaudited Financial Results for the 1st Quarter ended 30.06.2026.20 Jul 2026 · Result / Financial Results
Unaudited Financial Results for the 1st Quarter ended 30.06.2026.20 Jul 2026 · Board Meeting / Outcome of Board Meeting
Intimation of Schedule of Conference Call - Q1 FY- 2026-2715 Jul 2026 · Company Update / Analyst / Investor Meet
Vimta Labs Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/07/2026 ,inter alia, to consider and approve Unaudited Financial Results for ....15 Jul 2026 · Board Meeting / Board Meeting
Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30th June 20269 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Update on Payment of Dividend4 Jul 2026 · Company Update / General
Allotment of ESOPs under Vimta Labs Employee Stock Option Plan 20211 Jul 2026 · Company Update / Allotment of ESOP / ESPS
Trading Window Closure-Q1- 2026-2730 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Voting Results and Scrutinizer Report - 36th AGM held on 25th June 202625 Jun 2026 · AGM/EGM / AGM
Proceeding of the 36th AGM.25 Jun 2026 · AGM/EGM / AGM
Intimation of Schedule of Analyst/ Institutional Investor Meet2 Jun 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication - AGM & Annual Report2 Jun 2026 · Company Update / Newspaper Publication
Business Responsibility and Sustainability Report 2025-261 Jun 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 2.0000	18 Jun 2026	18 Jun 2026	—
Bonus issue 1:1	13 Jun 2025	13 Jun 2025	—
Dividend - Rs. - 2.0000	30 May 2025	30 May 2025	—
Final Dividend - Rs. - 2.0000	11 Jul 2024	—	—

Board meetings

30 Oct 2026 Board Meeting - Financial Results
20 Jul 2026 Board Meeting - Financial Results